Sphingosine kinase 2 was found to be a novel therapeutic target.4 As shown in our previous study, SK2 was overexpressed in MM cell lines and primary human bone marrow CD138+ myeloma cells. This evidence concerns the gene SDC1 and plasma cell myeloma.